Director Huda Y. Zoghbi filed a Form 4 with the SEC on August 12, 2026, disclosing transactions in Regeneron Pharmaceuticals, Inc. common stock dated August 10, 2026, including a stock option exercise and a same-day sale of shares.

Key Highlights

  • Reporting person: Huda Y. Zoghbi, identified as a Director of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
  • Option exercise: 800 shares of common stock were acquired on August 10, 2026, via exercise of a Non-Qualified Stock Option at an exercise price of $376.69 per share (transaction code M)
  • Same-day disposition: 800 shares of common stock were disposed of on August 10, 2026, at a price of $800 per share (transaction code S)
  • Post-transaction ownership: Following the reported transactions, Zoghbi directly holds 1,703 shares of common stock
  • Rule 10b5-1 plan: The transactions were made pursuant to a plan intended to comply with Rule 10b5-1(c), adopted on November 20, 2025
  • Option vesting: According to the filing, the exercised stock option vested in three equal annual installments, commencing one year after the date of grant, with an expiration date of January 3, 2027

Zoghbi's August 2026 Option Exercise and Share Disposition at Regeneron

According to the filing, Huda Y. Zoghbi, a director of Regeneron Pharmaceuticals, Inc., exercised a Non-Qualified Stock Option on August 10, 2026, acquiring 800 shares of common stock at the conversion or exercise price of $376.69 per share. Immediately prior to the exercise, the filing records that Zoghbi directly held 2,503 shares following that acquisition. The option carried an expiration date of January 3, 2027, and the filing notes it vested in three equal annual installments beginning one year after the grant date.

On the same date, August 10, 2026, the filing reports that 800 shares of common stock were disposed of at a price of $800 per share under transaction code S, reducing Zoghbi's directly held position to 1,703 shares. Both the acquisition and the disposition are described in the filing as having been made pursuant to a plan intended to comply with Rule 10b5-1(c), which was adopted on November 20, 2025. Regeneron Pharmaceuticals is a biotechnology company focused on the discovery, development, and commercialization of medicines, with its shares listed on NASDAQ:REGN.

The Form 4 was filed on August 12, 2026, and signed by Huda Y. Zoghbi. The filing reflects no indirect beneficial ownership positions for these transactions, with all reported holdings recorded as direct.

What Was Disclosed

The filing disclosed a same-day option exercise and share sale by Regeneron director Huda Y. Zoghbi on August 10, 2026, executed under a pre-established Rule 10b5-1(c) trading plan adopted November 20, 2025, leaving the director with a direct holding of 1,703 shares.